Eikon Therapeutics, Inc. (EIKN)

Market Cap	535.97M
Revenue (ttm)	n/a
Net Income	-342.06M
EPS	-32.19
Shares Out	54.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,425
Open	9.54
Previous Close	9.56
Day's Range	9.29 - 10.00
52-Week Range	7.90 - 17.40
Beta	n/a
Analysts	Buy
Price Target	24.80 (+150.51%)
Earnings Date	Aug 10, 2026

About EIKN

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent W...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2026
• Employees: 384
• Stock Exchange: NASDAQ
• Ticker Symbol: EIKN
• Website: https://eikontx.com

Analyst Summary

According to 6 analysts, the average rating for EIKN stock is "Buy." The 12-month stock price target is $24.8, which is an increase of 150.51% from the latest price.

Price Target

$24.8

(150.51% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 5, 2026

Data Sources Report a data error